Identification and external validation of IgA nephropathy patients benefiting from immunosuppression therapy.

ABSTRACT:

Background

Although IgA nephropathy (IgAN), an immune-mediated disease with heterogeneous clinical and pathological phenotypes, is the most common glomerulonephritis worldwide, it remains unclear which IgAN patients benefit from immunosuppression (IS) therapy.

Methods

Clinical and pathological data from 4047 biopsy-proven IgAN patients from 24 renal centres in China were included. The derivation and validation cohorts were composed of 2058 and 1989 patients, respectively. Model-based recursive partitioning, a machine learning approach, was performed to partition patients in the derivation cohort into subgroups with different IS long-term benefits, associated with time to end-stage kidney disease, measured by adjusted Kaplan-Meier estimator and adjusted hazard ratio (HR) usin

SUBMITTER: Chen T 

PROVIDER: S-EPMC7016365 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature